Narrative review / 2024
Resistance exercise is proposed as an adjunct to incretin-based weight loss pharmacotherapy to preserve lean mass.
This narrative review evaluates lean mass loss associated with incretin-based antiobesity medications and the role of resistance exercise. Peptides such as liraglutide, semaglutide, tirzepatide, and retatrutide induce ~15-24% weight loss in adults with overweight and obesity, but also cause rapid loss of lean mass (~10% or ~6 kg). Supervised resistance exercise training interventions longer than 10 weeks can elicit large increases in lean mass (~3 kg) and strength (~25%). The authors propose tailored resistance exercise training alongside incretin therapy to preserve lean mass while achieving fat loss.
- Study type
- Narrative review
- Who was studied
- Adults with overweight and obesity
- What was measured
- Weight loss, lean mass loss, body composition, and resistance exercise effects
THE PAPER
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, Green DJ. Diabetes Care, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.